# Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

> **NCT05760196** · PHASE2 · UNKNOWN · sponsor: **Xiangpan Li** · enrollment: 56 (estimated)

## Conditions studied

- Objective Response Rate

## Interventions

- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT05760196
- **Lead sponsor:** Xiangpan Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-09-30
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2023-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05760196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05760196, "Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05760196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*